A Study of IN026 in Participants With Refractory Gout

NCT07587684 | Not Yet Recruiting Phase 1 FDA Drug

• 1 other identifier: IN026-001
• Study Type: interventional
• Target: 16
• Locations: 0 countries
• Sites: N/A

Brief Summary

The goal of this clinical study is to learn if IN026 Injection is safe and works to lower uric acid levels in adults with refractory gout (gout that does not respond well to standard treatments). The main questions it aims to answer are:

• What medical problems do participants have when taking IN026, such as changes in vital signs, blood tests, or heart rhythm?
• How does the body absorb, process, and respond to IN026, and does it trigger an immune reaction?
• Does IN026 lower uric acid levels in the blood and reduce tophi? Investigator will start with lower doses of IN026 and slowly increase the dose to find the well-tolerated dose. Participants will:
• Receive IN026 through an intravenous (IV) drip into a vein at a set dose.
• Complete a screening period of up to 4 weeks, followed by treatment and check-ups for up to 20 weeks.
• Have blood and urine samples taken at set times to check safety and how the body responds to IN026.

Conditions

Refractory Gout

Keywords

Uricase; Gout; Uric acid; IN026; hyperuricemia; Metabolic Diseases; Refractory Gout; Safety; Pharmacokinetics; Pharmacodynamics; Efficacy; mRNA-LNP medicine; Rheumatic Diseases; Messenger RNA; Urate oxidase; immunogenicity

Outcome Measures

Primary Outcomes (1)

• Incidence of Adverse Events (AEs), Treatment-Emergent Adverse Events (TEAEs), and Serious Adverse Events (SAEs)

  From first dose (Week 1 Day 1) through end of study (Week 21)

Secondary Outcomes (8)

• Change from Baseline in Serum Uric Acid Concentration

  From baseline (Week 1 Day 1) through Week 21

• Change in Tophi from Baseline

  From baseline (Week 1 Day 1) through Week 21

• Plasma Concentration of IN026 mRNA Over Time

  At pre-specified timepoints from first dose (Week 1 Day 1) through Week 21

• Plasma Concentration of Ionizable Lipid SX-66 Over Time

  At pre-specified timepoints from first dose (Week 1 Day 1) through Week 21

• Serum Uricase Level Over Time

  At pre-specified timepoints from first dose (Week 1 Day 1) through Week 21

Study Arms (6)

IN026 at Dose-Level A

EXPERIMENTAL

Participants receive intravenous IN026 Injection at dose-level A on Week 1 Day 1 (W1D1). Following safety/tolerability assessment, participants may receive extra doses (up to 5 in total) at predefined frequency.

Drug: IN026 Injection

IN026 at Dose-Level B

EXPERIMENTAL

Participants receive intravenous IN026 Injection at dose-level B on Week 1 Day 1 (W1D1). Following safety/tolerability assessment, participants may receive extra doses (up to 5 in total) at predefined frequency.

Drug: IN026 Injection

IN026 at Dose-Level C

EXPERIMENTAL

Participants receive intravenous IN026 Injection at dose-level C on Week 1 Day 1 (W1D1). Following safety/tolerability assessment, participants may receive extra doses (up to 5 in total) at predefined frequency.

Drug: IN026 Injection

IN026 at Dose-Level D

EXPERIMENTAL

Participants receive intravenous IN026 Injection at dose-level D on Week 1 Day 1 (W1D1). Following safety/tolerability assessment, participants may receive extra doses (up to 5 in total) at predefined frequency.

Drug: IN026 Injection

IN026 at Dose-Level E

EXPERIMENTAL

Participants receive intravenous IN026 Injection at dose-level E on Week 1 Day 1 (W1D1). Following safety/tolerability assessment, participants may receive extra doses (up to 5 in total) at predefined frequency.

Drug: IN026 Injection

IN026 at Dose-Level F

EXPERIMENTAL

Participants receive intravenous IN026 Injection at dose-level F on Week 1 Day 1 (W1D1). Following safety/tolerability assessment, participants may receive extra doses (up to 5 in total) at predefined frequency.

Drug: IN026 Injection

Interventions

IN026 Injection DRUG

IN026 Injection is a lipid nanoparticle (LNP)-formulated mRNA therapeutic administered as an intravenous (IV) infusion

IN026 at Dose-Level A; IN026 at Dose-Level B; IN026 at Dose-Level C; IN026 at Dose-Level D; IN026 at Dose-Level E; IN026 at Dose-Level F

Eligibility Criteria

• Age: 18 Years - 75 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Can voluntarily sign the informed consent form (ICF) and comply with ICF and study protocol requirements.
• Male or female, 18-75 years old (inclusive) at screening.
• Meet 2015 ACR/EULAR gout classification criteria, in the intercritical phase of gout or acute flare resolved ≥2 weeks at screening.
• Serum uric acid ≥420 μmol/L (7 mg/dl) at screening.
• Meet the definition of refractory gout (poor uric acid control accompanied by severe gout symptoms)

You may not qualify if:

• Gout secondary to radiotherapy/chemotherapy, lead poisoning, organ transplantation, tumor, etc. at screening/baseline.
• Rheumatoid arthritis, infectious/septic arthritis, or other acute inflammatory arthritis at screening/baseline.
• Glucose-6-phosphate dehydrogenase (G6PD) deficiency history, or G6PD level below normal lower limit.
• Positive HBsAg; HCV antibody positive is excluded except those with sustained HCV-RNA negativity after standard treatment; HIV antibody positive; active syphilis.
• Presence of chronic liver diseases including active hepatitis, cirrhosis and alcoholic liver disease.
• Participants with a history of any of the following: serious cardiovascular diseases within 6 months prior to screening; or serious diseases of the digestive, respiratory, urinary, musculoskeletal, neuropsychiatric, hematological, or immune systems within 3 months prior to screening.
• Prolonged QTcF at screening.
• Uncontrolled or untreated hypertension at screening.
• Participants who have received medications that may affect endpoint assessment, such as other urate-lowering therapies, mRNA-LNP vaccine, PEGylated drugs and uricase agents.
• History of severe allergy, or known allergy to IN026 or its components.
• Participation in other clinical trials within 30 days prior to screening.
• Participants with poor compliance, or those deemed otherwise unsuitable for this study by the investigator.

Sponsors & Collaborators

• Union Hospital, Tongji Medical College, Huazhong University of Science and Technology: lead

MeSH Terms

Conditions

Gout; Hyperuricemia; Metabolic Diseases; Rheumatic Diseases

Condition Hierarchy (Ancestors)

Arthritis; Joint Diseases; Musculoskeletal Diseases; Crystal Arthropathies; Purine-Pyrimidine Metabolism, Inborn Errors; Metabolism, Inborn Errors; Genetic Diseases, Inborn; Congenital, Hereditary, and Neonatal Diseases and Abnormalities; Nutritional and Metabolic Diseases; Pathologic Processes; Pathological Conditions, Signs and Symptoms; Connective Tissue Diseases; Skin and Connective Tissue Diseases

Study Officials

• QiuBai Li

  Union Hospital, Tongji Medical College, Huazhong University of Science and Technology

  PRINCIPAL INVESTIGATOR

Central Study Contacts

QiuBai Li Union Hospital, Tongji Medical College, Huazhong University of

CONTACT

+86-27-85726338; qiubaili@hust.edu.cn

Study Design

• Study Type: interventional
• Phase: phase 1
• Allocation: NON RANDOMIZED
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: SEQUENTIAL
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Professor and Chief Physician, Head of Rheumatology Department

Study Record Dates

• First Submitted: April 24, 2026
• First Posted: May 14, 2026
• Study Start: May 1, 2026
• Primary Completion (Estimated): August 1, 2027
• Study Completion (Estimated): May 1, 2028
• Last Updated: May 14, 2026

Record last verified: 2026-05